This is a preview of subscription content, log in via an institution to check access.
Literatur
Curtin JA et al. Distinct Sets of Genetic Alterations in Melanoma. N Engl J Med. 2005; 353: 2135-47
Davies H et al. Mutations of the BRAF gene in human cancer. Nature. 2002; 417: 949-54
Hauschild A et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012; 380: 358-65
McArthur GA et al. Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol. 2014; 15: 323-32
Hamid O et al. Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for BRAF-Mutant Melanoma. Cancers (Basel). 2019; 11: 1642
Heinzerling L et al. Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management. ESMO Open. 2019; 4: e000491
Eikenberry J et al. Ocular side effects of target therapy and immunotherapy in patients with cutaneous malignant melanoma. Eur J Ophthalmol. 2020; https://doi.org/10.1177/1120672120930688
Cosgarea I et al. Update on the clinical use of kinase inhibitors in melanoma. J Dtsch Dermatol Ges. 2017; 15: 887-93
Daud A, Tsai K. Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma. Oncologist. 2017; 22: 823-33
Zimmer L et. al. Side effects of systemic oncological therapies in dermatology. J Dtsch Dermatol Ges. 2012; 10: 475-86
AWMF. S3-Leitliniezur Diagnostik, Therapie und Nachsorge des Melanoms. 2020; https://www.awmf.org/leitlinien/detail/ll/032-024OL.html abgerufen am 11. September 2020
Hassel JC et al. Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions. Cancer Treat Rev. 2017; 57: 36-49
Haanen J et al. Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy. Ann Oncol. 2020; https://doi.org/10.1016/j.annonc.2020.03.285
Abdel-Wahab N et al. Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature. J Immunother Cancer. 2019; 7: 106
De Bruyn P et al. Immune checkpoint blockade for organ transplant patients with advanced cancer. Curr Opin Oncol. 2019; 31: 54-64
Kähler KC et al. Side effect management during immune checkpoint blockade using CTLA-4 and PD-1 antibodies for metastatic melanoma - an update. J Dtsch Dermatol Ges. 2020; 18: 582-609
Lafabregue E et al. Two cases of pneumonitis induced by targeted therapy. Melanoma Res. 2019;29(4):441-3
Ros J, Muñoz-Couselo E. DRESS syndrome due to vemurafenib treatment: switching BRAF inhibitor to solve a big problem. BMJ Case Rep. 2018; 2018: bcr2018224379
Brunot A et al. Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma. JAMA Dermatol. 2020; https://doi.org/10.1001/jamadermatol.2020.2149
Weiss J et al. Therapy preferences in melanoma treatment—Willingness to pay and preference of quality versus length of life of patients, physicians, healthy individuals and physicians with oncological disease. Cancer Med. 2020; https://doi.org/ 10.1002/cam4.3191
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bohne, AS., Kähler, K. Nebenwirkungsmanagement unter dermatoonkologischer Systemtherapie. hautnah dermatologie 37, 38–41 (2021). https://doi.org/10.1007/s15012-020-4189-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s15012-020-4189-8